Učitavanje...
Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
BACKGROUND/AIMS: Nilotinib is used for treating patients with imatinib-sensitive or -resistant chronic myeloid leukemia (CML); however, nilotinib-resistant cases have been observed in recent years. In addition, a considerable number of patients receiving nilotinib developed diabetes. Metformin is a...
Spremljeno u:
| Izdano u: | Korean J Intern Med |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
The Korean Association of Internal Medicine
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8009173/ https://ncbi.nlm.nih.gov/pubmed/32241082 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2019.336 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|